Table II.
Analysis of prognostic factors by Cox regression analysis in ERα-positive postmenopausal breast cancer patients (n=195).
| Clinicopathological features | β coefficient | SEM | Wald value | P-value | Odds ratio | 95% CI |
|---|---|---|---|---|---|---|
| ERβ expression level | ||||||
| − | NA | NA | 14.911 | 0.001a | NA | NA |
| +/++ | –0.223 | 0.664 | 0.113 | 0.737 | 0.800 | 0.218–2.943 |
| +++ | 1.529 | 0.447 | 11.699 | 0.001a | 4.612 | 1.921–11.074 |
| Clinical stage | NA | NA | 7.687 | 0.021a | NA | NA |
| II | 1.440 | 0.629 | 5.246 | 0.022a | 4.223 | 1.231–14.484 |
| III | 2.084 | 0.768 | 7.366 | 0.007a | 8.037 | 1.784–36.199 |
| Chemotherapy | 0.325 | 0.514 | 0.398 | 0.528 | 1.384 | 0.505–3.792 |
| Radiotherapy | 0.266 | 0.472 | 0.317 | 0.573 | 1.305 | 0.517–3.293 |
| Endocrine therapy | 0.410 | 0.525 | 0.608 | 0.435 | 1.506 | 0.538–4.217 |
a
Statistically significant (P<0.05). SEM, standard error of the mean; CI, confidence interval; ER, estrogen receptor; NA, not applicable.